AMY1C: A Promising Drug Target and Biomarker for Alpha-amylase 1C Enzyme

Target Name: AMY1C

NCBI ID: G278

AMY1C

AMY1C: A Promising Drug Target and Biomarker for Alpha-amylase 1C Enzyme

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide. It is characterized by the accumulation of beta-amylase (尾-A) particles in the brain, which are thought to contribute to the destruction of nerve cells, ultimately leading to the development of the disease. The 尾-A particles are composed of the protein 尾-amylase (尾-A) and the protein alpha-glucosidase (伪-G), both of which are encoded by the gene AMY1C.

Recent studies have identified 伪-amylase 1C (AMY1C) as a promising drug target and biomarker for Alzheimer's disease. 伪-amylase 1C is a zinc-dependent enzyme that is involved in the breakdown of 尾-amylose, a key component of the amyloid protein that is thought to contribute to the development of Alzheimer's disease. The accumulation of 尾-amylose in the brain is believed to promote the formation of 尾-A particles, which are then thought to contribute to the destruction of nerve cells.

Drug Targeting

AMY1C has been identified as a potential drug target for Alzheimer's disease due to its involvement in the production of 尾-A particles. Several studies have shown that inhibiting the activity of AMY1C can reduce the formation of 尾-A particles in the brain, leading to potential therapeutic benefits in the treatment of Alzheimer's disease.

One of the most promising compounds that has been shown to inhibit the activity of AMY1C is a drug called AC123512, which is a small molecule inhibitor of AMY1C. In animal models of Alzheimer's disease, AC123512 has been shown to reduce the formation of 尾-A particles in the brain, suggesting that it has the potential to be a useful therapeutic agent for the treatment of Alzheimer's disease.

Biomarker

In addition to its potential use as a drug target, AMY1C has also been identified as a potential biomarker for Alzheimer's disease. The accumulation of 尾-amylose in the brain is thought to be a key event in the development of Alzheimer's disease, and therefore, the level of 尾-amylose in the brain can be seen as a biomarker for the disease.

Research has shown that the level of 尾-amylose in the brain is significantly increased in individuals with Alzheimer's disease compared to age-matched control individuals. Additionally, the level of 尾-amylose in the brain is directly proportional to the number of 尾-A particles, which are thought to contribute to the destruction of nerve cells in Alzheimer's disease. Therefore, the level of 尾-amylose in the brain can be used as a biomarker for the diagnosis and monitoring of Alzheimer's disease.

Conclusion

In conclusion, AMY1C is a promising drug target and biomarker for Alzheimer's disease. Its involvement in the production of 尾-A particles in the brain makes it a potential target for therapeutic intervention. The use of AC123512, a small molecule inhibitor of AMY1C, has been shown to be effective in reducing the formation of 尾-A particles in animal models of Alzheimer's disease. Furthermore, the accumulation of 尾-amylose in the brain can be used as a biomarker for the diagnosis and monitoring of Alzheimer's disease. Further research is needed to confirm the potential of AMY1C as a drug target and biomarker for Alzheimer's disease.

Protein Name: Amylase Alpha 1C

The "AMY1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMY1C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets